Lab Sciences
Top stories summarized by our editors
8/21/2017

A study in the journal Scientific Reports describes how scientists developed a fibrin-inspired biomaterial from modified peptides to speed blood clotting. In laboratory tests, the engineered sealant self-assembled into clot-like structures faster than natural fibrin, and it could ultimately be used to treat clotting disorders or bleeding caused by trauma.

More Summaries:
blood clotting
8/18/2017

Transmedics developed a portable perfusion and monitoring console dubbed the Organ Care System, which is capable of pumping blood through a heart being transported for transplant and may allow the organ to remain viable longer as it travels to its intended recipient. The system is being tested by physicians at Vanderbilt University Medical Center.

8/18/2017

The CDC announced the loss of a large stock of yellow fever vaccine during a Sanofi Pasteur plant relocation and said the US-licensed vaccine will not be available again until next year. The FDA has cleared Sanofi to bring in Stamaril, a yellow fever vaccine made in France, under the investigational drug program.

More Summaries:
Sanofi Pasteur, CDC, Sanofi, FDA, FDA
8/18/2017

A midstage study in the journal Blood found that 32% of patients treated with vorinostat prophylaxis developed
acute graft-versus-host disease in the year after hematopoietic stem cell transplantation from an 8/8 HLA-matched unrelated donor to treat a hematologic malignancy. After 30 days, levels of GVHD biomarkers were lower in patients treated with vorinostat.

8/18/2017

A meta-analysis of 12 late-stage randomized clinical trials by Australian researchers found that the use of novel oral anticoagulants resulted in a decline in intraocular bleeding in comparison to the use of warfarin for patients with venous thromboembolism or atrial fibrillation. The study in JAMA Ophthalmology included the NOACs apixaban, dabigatran, edoxaban and rivaroxaban.

Full Story:
eMPR
8/17/2017

Patients with chronic lymphocytic leukemia previously treated with ibrutinib had an overall response rate of 71% to CD19-specific chimeric antigen receptor T-cell therapy, according to a study in the Journal of Clinical Oncology. In 17 of 21 patients whose bone marrow was tested with high-resolution flow cytometry, no marrow disease was detected.

More Summaries:
bone marrow, Ibrutinib
8/17/2017

A blood test that detects DNA fragments released by malignant tumors accurately diagnosed 71% of early-stage colon cancers, 68% of early-stage ovarian cancers and 59% of early-stage breast and lung cancers in 200 patients previously diagnosed with cancer; and yielded no false positives in 44 cancer-free volunteers, researchers reported in Science Translational Medicine. More work on the assay is needed, but the ability to diagnose cancer at very early stages could save lives, says lead researcher Victor Velculescu.

Full Story:
HealthDay News
8/17/2017

More than 139,000 kidney patients in California received treatment at dialysis clinics in 2016, a 46% increase compared with eight years ago, according to the Office of Statewide Health Planning and Development. The increase has been credited to improved survival of kidney patients due to advances in treatment for infections and cardiovascular disease.

Full Story:
HealthLeaders Media
8/17/2017

A team of researchers from the Netherlands developed a liquid biopsy called thromboSeq that identified tumor RNA in thrombocytes with nearly 90% accuracy in diagnosing non-small-cell lung cancer, according to a study in the journal Cancer Cell.

8/16/2017

The FDA approved VBI Vaccines' investigational new drug application for its immunotherapy candidate VBI-1901, which is being developed as a treatment for patients with glioblastoma multiforme. A Phase I/IIa study of the drug is expected to be launched later this year.